Last reviewed · How we verify
Pyronaridine-artesunate (PA)
Pyronaridine-artesunate (PA) is a Antimalarial Small molecule drug developed by Liverpool School of Tropical Medicine. It is currently in Phase 3 development for Treatment of uncomplicated Plasmodium falciparum malaria. Also known as: Pyramax.
Pyronaridine-artesunate is a combination of pyronaridine and artesunate, which work together to inhibit the growth of malaria parasites.
Pyronaridine-artesunate is a combination of pyronaridine and artesunate, which work together to inhibit the growth of malaria parasites. Used for Treatment of uncomplicated Plasmodium falciparum malaria.
At a glance
| Generic name | Pyronaridine-artesunate (PA) |
|---|---|
| Also known as | Pyramax |
| Sponsor | Liverpool School of Tropical Medicine |
| Drug class | Antimalarial |
| Target | Dihydroorotate dehydrogenase, Beta-hematin formation |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Pyronaridine is a dihydroorotate dehydrogenase inhibitor, while artesunate is a beta-hematin formation inhibitor. This dual-action mechanism allows for effective treatment of malaria.
Approved indications
- Treatment of uncomplicated Plasmodium falciparum malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Safety of Antimalarials in the FIRst trimEster (PHASE3)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso (PHASE3)
- Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers (PHASE1)
- Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet (PHASE1)
- Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study (PHASE1)
- Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyronaridine-artesunate (PA) CI brief — competitive landscape report
- Pyronaridine-artesunate (PA) updates RSS · CI watch RSS
- Liverpool School of Tropical Medicine portfolio CI
Frequently asked questions about Pyronaridine-artesunate (PA)
What is Pyronaridine-artesunate (PA)?
How does Pyronaridine-artesunate (PA) work?
What is Pyronaridine-artesunate (PA) used for?
Who makes Pyronaridine-artesunate (PA)?
Is Pyronaridine-artesunate (PA) also known as anything else?
What drug class is Pyronaridine-artesunate (PA) in?
What development phase is Pyronaridine-artesunate (PA) in?
What are the side effects of Pyronaridine-artesunate (PA)?
What does Pyronaridine-artesunate (PA) target?
Related
- Drug class: All Antimalarial drugs
- Target: All drugs targeting Dihydroorotate dehydrogenase, Beta-hematin formation
- Manufacturer: Liverpool School of Tropical Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of uncomplicated Plasmodium falciparum malaria
- Also known as: Pyramax
- Compare: Pyronaridine-artesunate (PA) vs similar drugs
- Pricing: Pyronaridine-artesunate (PA) cost, discount & access